NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
GSK PLC GSK
11 fiscal years on record · GBP · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
£32.7B
▲ 4.1% vs FY2024
Dividend streak
2 yrs
Raised every year since 2024
EPS · FY25
£1.39
Dividend / sh · FY25
£0.66
Payout · FY25
47%
ROE · FY25
38.0%
Net margin · FY25
17.5%
Dividend coverage
2.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
GBP 32.7B
Revenue, FY2025 · full 11-year series below
Revenue
Net income
17 cents of every revenue dollar became profit this year.
Per share
GBP 1.39
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 2.1 times — the rest stayed in the company.
Profitability
38.0%
Return on equity, FY2025
ROE
Operating margin24.3%
Net margin17.5%
Return on assets9.5%
Each GBP of equity produced 38 cents of profit this year.
Returned to shareholders
GBP 4.0B
returned in FY2025 · dividends + net buybacks
Dividends paidGBP 2.7B
Net buybacksGBP 1.4B
Share of profit70.4%
Consecutive raises2 years
GBP 2.7B in dividends and GBP 1.4B in buybacks — 70% of the year's profit went back to shareholders.
Growth
+6.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.7%
+6.0%
+3.2%
Net income
−27.4%
−0.1%
−3.8%
EPS, diluted
−27.6%
−0.5%
−2.1%
Dividend / share
+2.5%
−8.0%
−1.9%
Returned to shareholders
+17.7%
+0.2%
+0.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
GBP 61.1B
total assets, end of FY2025
Total assetsGBP 61.1B
EquityGBP 16.4B
CashGBP 3.4B
Gross debtGBP 14.5B
Net debtGBP 11.1B
Current ratio0.82×
Net debt stands at 68% of equity.
History
11 fiscal years
Every figure from documents filed with the SEC · GBP
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue £B
32.7
31.4
30.3
29.3
24.7
24.4
33.8
30.8
30.2
27.9
23.9
Operating income £B
7.9
4.0
6.7
6.4
4.4
6.0
7.0
5.5
4.1
2.6
10.3
EBITDA £B
10.2
6.6
9.0
8.6
6.5
8.0
9.3
7.3
6.0
4.4
12.0
Income tax £B
1.1
0.5
0.8
0.7
0.1
0.1
1.0
0.8
1.4
0.9
2.2
Net income £B
5.7
2.6
4.9
15.0
4.4
5.7
4.6
3.6
1.5
0.9
8.4
EPS, diluted £
1.39
0.62
1.20
3.66
1.08
1.43
0.93
0.73
0.31
0.19
1.72
Dividend / sh £
0.66
0.61
0.58
0.61
1.00
1.00
80.00
80.00
80.00
0.80
0.80
Payout %
47
97
48
17
91
69
85
109
256
427
46
ROE %
38.0
19.1
41.2
116.6
29.6
44.2
61.2
195.2
290.2
81.1
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
41 of 42
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed